Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC. Estrogen and progesterone receptor testing in breast Cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38(12):1346–66. https://doi.org/10.1200/JCO.19.02309.
Badve S, Kumar G (eds.). Predictive Biomarkers in Oncology. Applications in Precision Medicine. Springer International Publishing 2019.
Google Scholar
Brahmer JR, Govindan R, Anders RA, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018;6:75. https://doi.org/10.1186/s40425-018-0382-2.
Google Scholar
College of American Pathologists. PD-L1 testing of patients with lung cancer for immunooncology therapies. CAP; 2021.
Google Scholar
Dzau VJ, Ginsburg GS, Chopra A, Goldman D, Green ED, Leonard DGB, McClellan M, Plump A, Terry SF, Yamamoto KR. Realizing the full potential of precision medicine in health and health care: a vital direction for health and health care. NAM perspectives. Discussion paper. Washington, DC: National Academy of Medicine; 2016. https://doi.org/10.31478/201609k.
CrossRef
Google Scholar
El-Deiry WS, et al. The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin. 2019;69(4):305–43. https://doi.org/10.3322/caac.21560.
CrossRef
PubMed
PubMed Central
Google Scholar
Elmore JG, Longton GM, Carney PA, et al. Diagnostic concordance among pathologists interpreting breast biopsy specimens. JAMA. 2015;313(11):1122–32. https://doi.org/10.1001/jama.2015.1405.
CAS
CrossRef
PubMed
PubMed Central
Google Scholar
García-Alfonso P, García-Carbonero R, García-Foncillas J, et al. Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol. 2020;22:1976–91. https://doi.org/10.1007/s12094-020-02357-z.
Garrido P, Conde E, de Castro J, Gómez-Román JJ, Felip E, Pijuan L, Isla D, Sanz J, Paz-Ares L, López-Ríos F. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2020;22:989–1003.
Google Scholar
Garrison LP Jr, Babigumira JB, Masaquel A, Wang BC, Lalla D, Brammer M. The lifetime economic burden of inaccurate HER2 testing: estimating the costs of false-positive and false-negative HER2 test results in US patients with early-stage breast Cancer. Value Health. 2015;18(4):541–6. https://doi.org/10.1016/j.jval.2015.01.012.
CrossRef
PubMed
Google Scholar
Heinmoller P, Baenfer G, Grzelinksi M, Alexander K, Jasani B. Quality control of immunohistochemical and in situ hybridization predictive for treatment: Experience from international guidelines and international quality control schemes. In: Sunil Badve, George Louis Kumar (Eds.), Predictive Biomarkers in Oncology, 525–37 - December 2018. https://doi.org/10.1007/978-3-319-95228-4_48.
Humphries MP, Bingham V, Abdullahi Sidi F, et al. Improving the diagnostic accuracy of the PD-L1 test with image analysis and multiplex hybridization. Cancers (Basel). 2020;12(5):1114. https://doi.org/10.3390/cancers12051114.
CAS
CrossRef
Google Scholar
Lhermitte B, et al. Adequately defining tumor cell proportion in tissue samples for molecular testing improves interobserver reproducibility of its assessment. Virchows Arch. 2017;470(1):21–7.
CrossRef
Google Scholar
Matias-Guiu X, Stanta G, Carneiro F, et al. The leading role of pathology in assessing the somatic molecular alterations of cancer: position paper of the European Society of Pathology. Virchows Archiv Int J Pathol. 2020;476(4):491–7. https://doi.org/10.1007/s00428-020-02757-0.
CrossRef
Google Scholar
McKean WB, Moser JC, Rimm D, Hu-Lieskovan S. Biomarkers in precision cancer immunotherapy: promise and challenges. Am Soc Clin Oncol Educ Book. 2020;40:e275–91. https://doi.org/10.1200/EDBK_280571.
CrossRef
PubMed
Google Scholar
Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, Chang DK, Garsed DW, Jonkers J, Ledermann JA, Nik-Zainal S. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020;31(12):1606–22.
Google Scholar
Nass SJ, Cohen MB, Nayar R, Zutter MM, Balogh EP, Schilsky RL, Hricak H, Elenitoba-Johnson KSJ. Improving cancer diagnosis and care: patient access to high-quality oncologic pathology. Oncologist. 2019;24(10):1287–90. https://doi.org/10.1634/theoncologist.2019-0261.
CrossRef
PubMed
PubMed Central
Google Scholar
Park JJH, Siden E, Zoratti MJ, Dron L, Harari O, Singer J. Lester RT. Thorlund K, Mills EJ. Systematic review of basket trials, umbrella trials, and platform trials: A landscape analysis of master protocols. Trials 2019, 20, 572.
Google Scholar
Plebani M. The detection and prevention of errors in laboratory medicine. Ann Clin Biochem. 2010;47(Pt 2):101–10. https://doi.org/10.1258/acb.2009.009222.
CrossRef
PubMed
Google Scholar
Wasielewski RV, Hasselmann S, Rüschoff J, Fisseler-Eckhoff A, Kreipe H. Proficiency testing of immunohistochemical biomarker assays in breast cancer. Virchows Arch. 2008;453(6):537–43. https://doi.org/10.1007/s00428-008-0688-4.
CAS
CrossRef
PubMed
Google Scholar
Zhang H, Moisini I, Ajabnoor RM, Turner BM, Hicks DG. Applying the new guidelines of HER2 testing in breast cancer. Curr Oncol Rep. 2020;22(5):51. https://doi.org/10.1007/s11912-020-0901-4.